An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2004-2005 season.
Identifieur interne : 000926 ( Main/Exploration ); précédent : 000925; suivant : 000927An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2004-2005 season.
Auteurs : P. OrrSource :
- Canada communicable disease report = Releve des maladies transmissibles au Canada [ 1188-4169 ] ; 2004.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Antienzymes (usage thérapeutique), Comités consultatifs, Enfant, Enfant d'âge préscolaire, Femelle, Grippe humaine (), Grippe humaine (médecine vétérinaire), Grippe humaine (virologie), Grippe humaine (épidémiologie), Humains, Mâle, Nourrisson, Ontario (épidémiologie), Programmes de vaccination, Sialidase (antagonistes et inhibiteurs), Surveillance de la population, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (usage thérapeutique), Vaccins inactivés (administration et posologie), Vaccins inactivés (effets indésirables), Vaccins inactivés (immunologie), Vaccins inactivés (usage thérapeutique), Virus de la grippe A (pathogénicité), États-Unis d'Amérique (épidémiologie).
- MESH :
- administration et posologie : Vaccins antigrippaux, Vaccins inactivés.
- antagonistes et inhibiteurs : Sialidase.
- effets indésirables : Vaccins antigrippaux, Vaccins inactivés.
- immunologie : Vaccins antigrippaux, Vaccins inactivés.
- médecine vétérinaire : Grippe humaine.
- pathogénicité : Virus de la grippe A.
- usage thérapeutique : Antienzymes, Vaccins antigrippaux, Vaccins inactivés.
- virologie : Grippe humaine.
- épidémiologie : Grippe humaine, Ontario, États-Unis d'Amérique.
- Adolescent, Adulte, Adulte d'âge moyen, Comités consultatifs, Enfant, Enfant d'âge préscolaire, Femelle, Grippe humaine, Humains, Mâle, Nourrisson, Programmes de vaccination, Surveillance de la population.
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- Adolescent, Adult, Advisory Committees, Child, Child, Preschool, Enzyme Inhibitors (therapeutic use), Female, Humans, Immunization Programs, Infant, Influenza A virus (pathogenicity), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (immunology), Influenza Vaccines (therapeutic use), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Influenza, Human (veterinary), Influenza, Human (virology), Male, Middle Aged, Neuraminidase (antagonists & inhibitors), Ontario (epidemiology), Population Surveillance, United States (epidemiology), Vaccines, Inactivated (administration & dosage), Vaccines, Inactivated (adverse effects), Vaccines, Inactivated (immunology), Vaccines, Inactivated (therapeutic use).
- MESH :
- chemical , administration & dosage : Influenza Vaccines, Vaccines, Inactivated.
- chemical , adverse effects : Influenza Vaccines, Vaccines, Inactivated.
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , immunology : Influenza Vaccines, Vaccines, Inactivated.
- chemical , therapeutic use : Enzyme Inhibitors, Influenza Vaccines, Vaccines, Inactivated.
- geographic , epidemiology : Ontario, United States.
- epidemiology : Influenza, Human.
- pathogenicity : Influenza A virus.
- prevention & control : Influenza, Human.
- veterinary : Influenza, Human.
- virology : Influenza, Human.
- Adolescent, Adult, Advisory Committees, Child, Child, Preschool, Female, Humans, Immunization Programs, Infant, Male, Middle Aged, Population Surveillance.
PubMed: 15239483
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2004-2005 season.</title>
<author><name sortKey="Orr, P" sort="Orr, P" uniqKey="Orr P" first="P" last="Orr">P. Orr</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15239483</idno>
<idno type="pmid">15239483</idno>
<idno type="wicri:Area/Main/Corpus">000985</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000985</idno>
<idno type="wicri:Area/Main/Curation">000985</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000985</idno>
<idno type="wicri:Area/Main/Exploration">000985</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2004-2005 season.</title>
<author><name sortKey="Orr, P" sort="Orr, P" uniqKey="Orr P" first="P" last="Orr">P. Orr</name>
</author>
</analytic>
<series><title level="j">Canada communicable disease report = Releve des maladies transmissibles au Canada</title>
<idno type="ISSN">1188-4169</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Advisory Committees</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Enzyme Inhibitors (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Immunization Programs</term>
<term>Infant</term>
<term>Influenza A virus (pathogenicity)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (adverse effects)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza Vaccines (therapeutic use)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (veterinary)</term>
<term>Influenza, Human (virology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neuraminidase (antagonists & inhibitors)</term>
<term>Ontario (epidemiology)</term>
<term>Population Surveillance</term>
<term>United States (epidemiology)</term>
<term>Vaccines, Inactivated (administration & dosage)</term>
<term>Vaccines, Inactivated (adverse effects)</term>
<term>Vaccines, Inactivated (immunology)</term>
<term>Vaccines, Inactivated (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Antienzymes (usage thérapeutique)</term>
<term>Comités consultatifs</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (médecine vétérinaire)</term>
<term>Grippe humaine (virologie)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Ontario (épidémiologie)</term>
<term>Programmes de vaccination</term>
<term>Sialidase (antagonistes et inhibiteurs)</term>
<term>Surveillance de la population</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (effets indésirables)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins antigrippaux (usage thérapeutique)</term>
<term>Vaccins inactivés (administration et posologie)</term>
<term>Vaccins inactivés (effets indésirables)</term>
<term>Vaccins inactivés (immunologie)</term>
<term>Vaccins inactivés (usage thérapeutique)</term>
<term>Virus de la grippe A (pathogénicité)</term>
<term>États-Unis d'Amérique (épidémiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Enzyme Inhibitors</term>
<term>Influenza Vaccines</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Ontario</term>
<term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins inactivés</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins inactivés</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins inactivés</term>
</keywords>
<keywords scheme="MESH" qualifier="médecine vétérinaire" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Influenza A virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antienzymes</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins inactivés</term>
</keywords>
<keywords scheme="MESH" qualifier="veterinary" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term>
<term>Ontario</term>
<term>États-Unis d'Amérique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Advisory Committees</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Humans</term>
<term>Immunization Programs</term>
<term>Infant</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Population Surveillance</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Comités consultatifs</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Programmes de vaccination</term>
<term>Surveillance de la population</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15239483</PMID>
<DateCompleted><Year>2004</Year>
<Month>08</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised><Year>2005</Year>
<Month>11</Month>
<Day>22</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1188-4169</ISSN>
<JournalIssue CitedMedium="Print"><Volume>30</Volume>
<PubDate><Year>2004</Year>
<Month>Jun</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Canada communicable disease report = Releve des maladies transmissibles au Canada</Title>
<ISOAbbreviation>Can. Commun. Dis. Rep.</ISOAbbreviation>
</Journal>
<ArticleTitle>An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2004-2005 season.</ArticleTitle>
<Pagination><MedlinePgn>1-32</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Orr</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><CollectiveName>National Advisory Committee on Immunization</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<Language>fre</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Canada</Country>
<MedlineTA>Can Commun Dis Rep</MedlineTA>
<NlmUniqueID>9303729</NlmUniqueID>
<ISSNLinking>1188-4169</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D026683" MajorTopicYN="N">Advisory Committees</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>7</Month>
<Day>9</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2004</Year>
<Month>8</Month>
<Day>7</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>7</Month>
<Day>9</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15239483</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list></list>
<tree><noCountry><name sortKey="Orr, P" sort="Orr, P" uniqKey="Orr P" first="P" last="Orr">P. Orr</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000926 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000926 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= GrippeCanadaV3 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:15239483 |texte= An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2004-2005 season. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:15239483" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a GrippeCanadaV3
This area was generated with Dilib version V0.6.35. |